Zacks.com on MSN21h
AMGN Stock Down Despite Strong Data From Obesity Drug StudyKey Takeaways A new Amgen weight reduction drug, MariTide, has bred successful results after a 52-week study. Still, AMGN ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback